Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Next generation sequencing of a unique set of glycovariant MC38 mouse colorectal cancer cell lines generated with CRISPR-Cas9 and CRISPR-dCas-VPR technology

ABSTRACT: To investigate the effect of different tumor-associated glycans, mouse colorectal cancer cells (MC38 cell line) were genetically modified using CRISPR-Cas9 and CRISPR-dCas-VPR technology targeting different genes involved in glycosylation pathways. To study the effect of altered glycosylation at the transcriptional level, next generation sequencing was performed on the entire panel of glycovariant MC38 cell lines. The MC38 knockout cell lines created with the CRISPR-Cas9 technology are: MC38-MOCK#1, MC38-CMAS KO, MC38-COSMC KO, MC38-CMAS+COSMC KO. The MC38 overexpressing cell lines generated with the CRISPR-dCas9-VPR technology are: MC38-MOCK#2, MC38-FUT4, MC38-FUT9. Details on the cell lines can be found in the corresponding manuscript(s).

ORGANISM(S): Mus musculus

PROVIDER: GSE143700 | GEO | 2020/08/05

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Next generation sequencing of a unique set of glycovariant MC38 mouse colorectal cancer cell lines generated with CRISPR-Cas9 and CRISPR-dCas-VPR technology

Project description:Next generation sequencing of a unique set of glycovariant MC38 mouse colorectal cancer cell lines generated with CRISPR-Cas9 and CRISPR-dCas-VPR technology

| PRJNA601332 | ENA

Keratinocyte CRISPR screens

Project description:Immortalised HaCaT keratinocytes were transduced with Cas9 and the CRISPR-KO v1.1 genome-wide gRNA library. The gRNA library was prepared from genomic DNA isolated 14 days post library transduction. gRNA representation will be compared to the original CRISPR-KO v1.1 library to reveal genes essential for HaCaT survival and growth.

| EGAS00001002714 | EGA

Epigenetically-controlled tumor antigens derived from splice junctions between exons and transposable elements [ChIP-seq]

Project description:To analyze regulation of JET expression, we generated Setdb1-deficient MC38 and B16OVA cells, using lentivirus-based CRISPR/Cas9. Ctrl and KO cells lines were used to perform ChIP-seq against H3K9me3 and H3K9Ac, with 3 biological replicates.

2022-11-22 | GSE208567 | GEO

Biological Plasticity Rescues Target Activity in CRISPR Knock Outs

Project description:Systematic investigation of residual protein expression in frameshift KO mutations derived from CRISPR-Cas9 in clonal cell lines

2019-09-03 | PXD010335 | Pride

CRISPR/dCas-based modulation of bacterial IS-transposition

Project description:CRISPR/dCas-based modulation of bacterial IS-transposition

| PRJNA435096 | ENA

A human BCRP (ABCG2) cell line without MDR1 (ABCB1) background –improved models for drug efflux studies using CRISPR-Cas

Project description:Proteomics data of two MDCK-cMDR1 KO cell lines expressing either hBCRP or hMDR1 drug transporters, generated with CRISPR-Cas9.

2020-11-09 | PXD020238 | Pride

Scaffold RNA engineering in type V CRISPR-Cas systems: a potent way to enhance gene expression in the yeast Saccharomyces cerevisiae.

Project description:New, orthogonal transcription factors in eukaryotic cells have been realized by engineering nuclease-deficient CRISPR-associated proteins and/or their guide RNAs. In this work, we present a new kind of orthogonal activators, in Saccharomyces cerevisiae, made by turning type V CRISPR RNA into a scaffold RNA (ScRNA) able to recruit a variable number of VP64 activation domains. The activator arises from the complex between the synthetic ScRNA and DNase-deficient type V Cas proteins: dCas12e and denAsCas12a. The transcription activation achieved via the newly engineered dCas:ScRNA system is up to 4.7-fold higher than that obtained with the direct fusion of VP64 to Cas proteins. The new transcription factors have been proven to be functional in circuits such as Boolean gates, converters, multiplex-gene and metabolic-pathway activation. Our results extend the CRISPR-Cas-based technology with a new effective tool that only demands RNA engineering and improves the current design of transcription factors based on type V Cas proteins.

2023-12-05 | GSE249355 | GEO

USP7 CRISPR knock-out in T-ALL cells [Molt4_CRISPR_RNA-seq]

Project description:RNAseq analysis of USP7 CRISPR KO in T-ALL cell lines. Genetically modified T-ALL cells were generated using CRISPR-Cas9 technology. Briefly, the sgRNA was designed with at least 3bp of mismatch to any other site in the human genome to mitigate the risk of off-target editing. To generate the modified cells, 400,000 cells were transiently co-transfected with / without 0.5 ug pmaxGFP plasmid (Lonza), with 33 pmol spCas9 protein, 100 pmol chemically modified sgRNA (Synthego), and 100 pmol of blocking ssODN (IDT) via nucleofection (Lonza), using solutions and programs according to the manufacturer’s recommended protocol. Five days post-nucleofection, cells were single-cell sorted by FACs into 96-well plates. Cells were clonally expanded and verified the desired modification via targeted deep sequencing

2021-03-09 | GSE148523 | GEO

Gene expression profiling of a model of CRISPR-mediated insulator disruption in the MMP locus in triple-negative breast cancer cell lines

Project description:Using CRISPR-Cas9 technology, we stably disrupted an insulator element in two different TNBC cell lines. The aim of this experiment was to characterize the transcriptomic profile using RNA-seq. For this experiment, we selected three biological replicates of MDA-MB-231 (WT and IE8dis).

2023-08-31 | E-MTAB-12823 | biostudies-arrayexpress

Chromatin architecture profiling of a model of CRISPR-mediated insulator disruption in the MMP locus in triple-negative breast cancer cell lines

Project description:Using CRISPR-Cas9 technology, we stably disrupted an insulator element in two different TNBC cell lines. The aim of this experiment was to characterize the chromatin architecture profile using Hi-C. For this experiment, we selected three biological replicates of MDA-MB-231 (WT and IE8dis).

2023-08-31 | E-MTAB-12825 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data